Vertex and Ono Ink Deal to Develop and Commercialize Povetacicept in Japan and South Korea
Vertex and Ono Pharmaceutical Forge Strategic Partnership to Develop and Commercialize Povetacicept in Japan and South Korea In a move that underscores the growing international collaboration in advancing treatment for…
Amgen Unveils Phase 2 Obesity Trial Results for Monthly Maritide at ADA’s 85th Scientific Sessions
Amgen Unveils Full Phase 2 Data on Monthly Obesity Drug MariTide, Highlighting Robust Weight Loss and Cardiometabolic Benefits at ADA 2024 Amgen has presented comprehensive results from the first part…
Datroway Wins U.S. Approval for Previously Treated Advanced EGFR-Mutated NSCLC
Datroway Gains Accelerated FDA Approval for Previously Treated EGFR-Mutated Advanced Non-Small Cell Lung Cancer The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Datroway (datopotamab deruxtecan, also…
Merck’s WINREVAIR Succeeds in Phase 3 Trial for Pulmonary Arterial Hypertension
Merck’s WINREVAIR Achieves Primary Endpoint in Phase 3 HYPERION Trial for Pulmonary Arterial Hypertension in Newly Diagnosed Adults Merck, operating as MSD outside the United States and Canada, has announced…
EU Backs Ozempic for PAD in Type 2 Diabetes, Highlighting Semaglutide’s Broader Benefits
Novo Nordisk Secures EU CHMP Backing for Ozempic® Label Expansion in PAD, Reinforcing Semaglutide’s Role in Managing Type 2 Diabetes with Comorbidities Novo Nordisk has announced that the European Medicines…
Exelixis: Zanzalintinib Combo Boosts Survival in Phase 3 Colorectal Cancer Trial
Exelixis Reports Positive Phase 3 Results for Zanzalintinib and Atezolizumab Combo in Metastatic Colorectal Cancer Exelixis, has announced promising topline results from the STELLAR-303 phase 3 pivotal clinical trial, a…
CHMP Recommends EU Approval of Sarclisa for Newly Diagnosed Multiple Myeloma
Sarclisa Moves Closer to EU Approval for Frontline Treatment of Transplant-Eligible Multiple Myeloma Patients The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive…
Roche’s NXT007 Shows Early Promise for Normalising Clotting in Haemophilia A
Roche Unveils Promising Phase I/II Data for Next-Generation Bispecific Antibody NXT007 in Hemophilia A, Signaling a Major Step Toward Phase III Development Roche has shared encouraging new data from its…
Novo Nordisk’s CagriSema Shows 22.7% Weight Loss in REDEFINE 1 Study Published in NEJM
Novo Nordisk’s CagriSema Delivers Up to 22.7% Weight Loss in Obese or Overweight Adults, REDEFINE 1 Trial Results Published in NEJM In a significant advancement for the treatment of obesity…
Novo Nordisk: Phase 3 Data Shows Mim8 Well-Tolerated After Switch from Emicizumab in Hemophilia A
Novo Nordisk Unveils Positive Phase 3b Results for Mim8 in Hemophilia A: Seamless Switch from Emicizumab Shows Safety, Efficacy, and High Patient Satisfaction Novo Nordisk presented new findings from its…
CHMP Recommends Third Indication for Bayer’s Nubeqa in Advanced Prostate Cancer Patients
CHMP Recommends Expanded Use of Bayer’s Nubeqa™ (Darolutamide) for Advanced Prostate Cancer Following Positive ARANOTE Trial Results The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines…
Vertex Reports Favorable Zimislecel Outcomes for Type 1 Diabetes at ADA Scientific Sessions
Vertex Showcases Groundbreaking Data for Zimislecel in Type 1 Diabetes at ADA 85th Scientific Sessions Vertex Pharmaceuticals Incorporated has announced compelling new clinical data from its ongoing FORWARD-101 trial, underscoring…